Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neuroblastoma 1Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Irinotecan 3Temozolomide 2Doxorubicin 2Cyclophosphamide 2robatumumab 1palbociclib 1liposomal doxorubicin 1cc-486 1Vincristine 1Topotecan 1Taxes 1Surveys and Questionnaires 1Quality of Life 1Psychology, Positive 1Patient Reported Outcome Measures 1Paclitaxel 1Observation 1Molecular Diagnostic Techniques 1Methods 1Lomustine 1Injections 1Immunotherapy 1Ifosfamide 1Genetic Testing 1Gemcitabine 1Etoposide 1Drug Therapy 1Cyproheptadine 1Carboplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × robatumumab × CNS × Clear all
NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡